The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | CD22-directed CAR-T for FL, MCL, and other NHL subtypes: toxicity and sequencing insights
Matthew Frank, MD, PhD, Stanford University, Stanford, CA, shares insights into CD22-directed CAR-T therapy in follicular lymphoma (FL), mantle cell lymphoma (MCL), and other non-Hodgkin lymphomas (NHL) subtypes, noting its favorable toxicity profile, although the reason for this remains unknown. Dr Frank highlights that currently, CD22-directed CAR therapy should follow a pre-existing CAR and be guided by the patient’s personal profile. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
